Cytodel

Developing recombinant botulinum toxin derivatives for targeted intraneuronal therapeutic delivery

placeNew York City, New York, United States calendar_todayFounded 2012 groups6 employees language cytodel.com

Registered entities

Investor mix

2 investors on record.

Investor typeCountShare
Venture capital150%
Other / undisclosed150%
Coming soon